INTRODUCTION
============

Genitourinary cancers are commonly diagnosed malignancies worldwide and significantly impact human health. Prostate cancer (PC) is the most commonly diagnosed malignancy in men in the United States and second most frequent cancer in men worldwide in 2018 \[[@B1][@B2]\]. Bladder and kidney cancers are globally the sixth and ninth most common cancers, respectively, in men \[[@B1]\]. European countries have the highest incidence of these all three genitourinary cancers \[[@B1][@B3]\]. Furthermore, the incidence and mortality of these three genitourinary cancers have increased 2.5- and 1.6-fold between 1990 and 2013, respectively \[[@B4]\]. This substantial increasing trend of global genitourinary cancer burden has not subsided.

While randomized controlled trials (RCTs) provide the highest level of evidence, they are not always feasible and sometimes impossible \[[@B5]\]. Narrow eligibility criteria and highly controlled settings of RCTs can rather limit their applicability \[[@B5]\]. Alternatively, high-quality cohort studies sometimes generate valuable information that is generally applicable, even in situations in which RCT is impractical \[[@B6]\].

Accordingly, we aimed to develop a prospective, comprehensive, multidisciplinary, bio-bank-linked cohort based on standard real practice for PC, renal cell carcinoma (RCC), and urothelial cancer (UC). After preparing for three years, we established the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC) in March 2016. The major goals of the SUPER-GUC are as follows: 1) to conduct comparative outcome studies between various treatment options, 2) to identify prognostic factors for disease progression and mortality, 3) to facilitate various type of translational research including genetic or molecular profiling and biomarker studies, 4) to understand patients\' quality of life (QoL) and promote QoL research including a patient-oriented outcome study and comparative-effectiveness research \[[@B7]\], 5) to investigate changes in body composition and its impacts on outcomes, and 6) to understand the influence of aging and fragility on treatment and cancer in elderly patients.

The present paper describes the design and methodology of SUPER-GUC. Furthermore, we summarize current patient enrollment status and basic demographics.

MATERIALS AND METHODS
=====================

1. Ethics statement
-------------------

All study protocols for SUPER-PC, SUPER-RCC, and SUPER-UC were approved by the Institutional Review Board (IRB) of Seoul National University Hospital (Seoul, Korea). The approval numbers are H-1506-121-682, H-1506-120-682, and H-1506-122-682, respectively. Informed consent was obtained by all subjects when they were enrolled.

2. Organization
---------------

As faculty providing direct treatment, four uro-oncologists, two medical oncologists, and one radiation oncologist, who mainly manage treat genitourinary cancer patients, participate with this cohort. They exclusively manage almost all genitourinary cancer patients in our tertiary high-volume institution. As supporting faculty, three uroradiologists, one nuclear medicine physician, and one uropathologist exclusively interpret medical images and pathological results. Participating faculty are all well-experienced, dedicated specialists in their field. We have one permanent information technology (IT) engineer consultant and three IT advisors.

3. Sub-cohorts and eligibility criteria
---------------------------------------

SUPER-GUC consists of three cohorts based on cancer type, SUPER-PC, SUPER-RCC, and SUPER-UC. Each cohort is composed of several sub-cohorts based on treatment or disease status. Names of the sub-cohorts and their eligibility criteria are described in [Table 1](#T1){ref-type="table"}.

4. Patient process, data collection, and bio-specimen repository
----------------------------------------------------------------

In principle, the cohort is based on real clinical practice, and the study does not interfere with actual practice. All patients are enrolled following provision of written informed consent for the cohort study based on cancer type as well as for the additional bio-specimen registry.

All data were collected using the Research Electronic Data Capture (REDCap) system in an independent server with a triple back-up system. REDCap is a secure, web-based application designed to support data capture for research studies \[[@B8]\]. Electronic case-report forms (eCRF) consist of several forms (designated as 'instruments' in REDCap), and selected forms can be repeatedly entered to capture longitudinal data. Furthermore, some common forms are shared by all sub-cohorts in SUPER-GUC. We categorized data entering forms as once entering, repeatedly entering, and revisingly entering forms. After entering all data in once entering type form, it is finalized and locked. We can handle repeating data using repeatedly entering forms, such as questionnaires or transurethral resection of bladder tumor information. In revisingly entering forms, we can revise data until it is finalized. For instance, the last follow-up date is revised following every hospital visit in this of form.

We constructed eCRF forms to be as detailed as possible. For example, SUPER-PC-Radical Prostatectomy (RP) has 20 forms with 784 fields. [Table 2](#T2){ref-type="table"} shows construction of the eCRF for SUPER-PC-RP. [Fig. 1](#F1){ref-type="fig"} depicts the exemplary data collection process for SUPER-PC-RP with eCRFs. Each sub-cohort has its own predefined data collection process.

We selected questionnaires according to two principles. First, the Korean version should be validated and easily incorporated in daily practice. Some questionnaires were already validated, and some were validated by our team for SUPER-GUC. For measuring health-related utility and general QoL, we universally use EQ-5D-5L across all sub-cohorts. In addition, we use the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) for PC patients. The 15-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-15) and the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) were selected as disease-specific questionnaires for RCC and cystectomy patients, respectively. We also use the Convalescence And Recovery Evaluation (CARE) questionnaire to evaluate short-term (≤3 months) QoL after major surgery \[[@B9]\]. The G8 geriatric screening tool is used for patients who are 65 years or older \[[@B10][@B11]\].

Surgical complications are evaluated and collected using the revised Clavien--Dindo system and European Association of Urology (EAU) guidelines \[[@B12][@B13]\]. All treatment-related adverse events are evaluated with the same forms of the Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0.3. Regardless of treating departments, we standardized all evaluation formats, including questionnaires and adverse events assessment.

To measure body composition based on bioelectrical impedance analysis (BIA), we use the InBody 570 (InBody Co., Ltd., Seoul, Korea). This is a well-established method to determine body composition such as lean muscle mass and body fat mass \[[@B14][@B15][@B16]\].

We collect patients\' pre-treatment whole blood, serum, buffy coat, plasma, and urine samples at the time of entering new sub-cohorts. Collected samples are divided in microvials and stored in a −80℃ deep freezer or −195℃ liquid nitrogen container according to the sample type at the Seoul National University Hospital Human Biobank. Tumor and normal tissues are collected in the operating room or frozen biopsy room up to six vials each and immediately stored in a −195℃ liquid nitrogen tank at the Seoul National University Hospital Cancer Tissue Bank. These two banking systems are qualified, centralized bio-banking systems at our institution that have been in operation for almost a decade. Formalin-fixed, paraffin-embedded tissue blocks are available in virtually 100% patients managed by the Department of Pathology.

5. Outcome measurements
-----------------------

A major point of interest regarding the cohort is oncologic outcomes. Baseline cancer status and general condition are evaluated at the time of enrollment for each sub-cohort. Treatment response, time of recurrence, and survival are evaluated. Furthermore, baseline cancer status and oncologic outcome are repeatedly evaluated for every single major treatment in advanced or metastatic disease. Date and cause of death are confirmed by regular linkage with death registry at the Statistics Korea.

Functional outcomes measured in PC patients include urinary and sexual function. For the nephrectomy sub-cohort, renal function was also determined using estimated glomerular filtration rate or renal scan and progression to end-stage renal disease.

6. Statistical analysis
-----------------------

We summarize current enrollment status, basic demographics, and sampling information. Data are expressed as the mean±standard deviation. A p-values \<0.05 were considered statistically significant. All statistical analyses were performed using R for Windows, version 3.5.1 (<http://www.r-project.org>).

RESULTS
=======

The first patient was enrolled March 7, 2016 in SUPER-PC. At the end of December, 2018, a total of 929, 796, and 1,221 patients were enrolled in SUPER-PC, SUPER-RCC, and SUPER-UC, respectively. Results of patient enrollment are summarized in [Table 3](#T3){ref-type="table"}. [Table 4](#T4){ref-type="table"} shows rates of study participation, bio-sampling, and fresh frozen tumor banking and baseline characteristics of surgical sub-cohorts.

For SUPER-PC-RP, we also developed an online interactive data visualization and analysis platform using Tableau Server ver. 10.3.1 (Tableau Software, Inc., Seattle, WA, USA) ([Fig. 2](#F2){ref-type="fig"}) \[[@B17][@B18]\]. Results are interactively presented in real time as we change the dimensional variables.

DISCUSSION
==========

There are several types of prospective cohort or registries \[[@B19]\]. Population-based cohorts systematically collect data on all or randomly selected patients with a certain disease in a given geographic area within a given time \[[@B20]\]. They usually link with national claims data and statistics \[[@B21]\]. Thus, representativeness and generalizability are the advantage, while incomplete or inaccurate data coding and lack of detailed information are potential serious pitfalls \[[@B21]\]. Community and/or multicenter cohorts may be the most common form of cohorts \[[@B19]\]. A greater number of involved institutions increases the generalizability. However, relatively high cost, standardization between institutions, and maintaining high quality are ongoing challenges. Single institutional cohort may be limited by its lack of representativeness; however, it has the advantage of being able to collect additional detailed information \[[@B19]\]. Furthermore, it is relatively easy to maintain high quality.

Traditionally, numerous studies were conducted as retrospective single center case series, rather than an actual cohort \[[@B6][@B19][@B22]\]. Occasionally, the reports insisted they used a prospectively collected database, but they were usually limited by many biases and missing data. Thus, we initiated SUPER-GUC as a prospective, single institutional cohort with flexible structure; this can be extended as multicenter cohort in the future. Additionally, although we started it as a single institutional cohort, we endeavored to overcome limitation of single-center cohort and maximize its quality and potential for utilization.

First, we organized it as multidisciplinary cohort, which collects data from all related departments using standardized methods. We also unified data collection forms and timing, especially QoL questionnaires and adverse events assessment. Patients can select different treatment provided by different specialties, even for the same disease status. For example, localized PC patients may undergo either RP provided by a urologist or radiation therapy provided by a radiation oncologist \[[@B23]\]. Furthermore, patients may have sequential treatments through different departments dependent upon disease progression. For instance, after radical cystectomy performed by a urologist, adjuvant or palliative chemotherapy can be provided by a medical oncologist. Based on this multidisciplinary endeavor, we can compare any treatment outcome as well as that of any follow-up evaluation throughout long-term treatment without cessation.

Next, we constructed a comprehensive cohort consisting of sub-cohorts for all possible disease conditions and treatments. Patients may be entered to a specific sub-cohort from other sub-cohorts dependent upon disease progression; alternatively, newly referred patients may be enrolled directly to the sub-cohort. This sub-cohort structure allows us to effectively recruit patients, especially those with a more advanced condition, and collect specific detailed data focusing on the status of each patient. The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is one of the most successful prospective PC cohorts \[[@B19][@B24]\]. This cohort recruited over 15,000 patients at all stages from 43 urology practices for three decades \[[@B19][@B24][@B25]\]. However, only newly diagnosed PC patients are eligible in a single-phase design \[[@B24][@B25]\]. Therefore, localized cancer and initial treatment are highly focused, whereas data after progression or later phase treatment (e.g., androgen receptor-targeted treatment for castration-resistant PC) are limited. We expect we can overcome this using our comprehensive, multi-sub-cohort design.

Third, the bio-specimen repository is another important feature of SUPER-GUC. Traditionally, all formalin-fixed, paraffin-embedded tissue blocks of surgical specimens are stored in our institution. However, we extend this by collecting pre-treatment blood and urine in most cases and freshly frozen tumor and normal tissues in all possible cases. These bio-specimens are stored and managed by qualified, centralized bio-banking systems that are certified by the government. Thus, SUPER-GUC can support a variety of translational research, such as biomarker or genetic profiling studies. For instance, we are currently conducting a study to evaluate the association between congenital immune deficiency with cancer characteristics and outcomes in 540 bladder cancer patients. Several urine biomarker studies for bladder cancer were conducted or are currently in progress. We also performed comprehensive genetic characterization of transcription factor E3 (TFE3)-overexpressed RCC using the SUPER-RCC cohort. Recently, we conducted a predictive serum biomarker study that differentiates benign tumors from RCC using SUPER-RCC-Nephrectomy (Nx). We are cautiously confident that SUPER-GUC will be an important translational research platform.

Fourth, even though it is institutional cohort, mortality information is regularly collected from the government death registry at the Statistics Korea. Accordingly, we can assure survival data, the most important outcome of SUPER-GUC.

Finally, we collect a variety of data for comprehensive future studies. Using validated instruments, patient-reported health-related QoL are evaluated. Since usual health-related QoL questionnaires cannot sensitively capture differences in QoL between surgery types, we also collect CARE questionnaire before and within 3 months after operation \[[@B9]\]. To evaluate the effect of vulnerability, we also use the G8 geriatric screening tool for elderly patients for all treatments \[[@B10][@B11]\]. Moreover, to more precisely measure muscle and fat mass and determine their association with outcome, we regularly measure body composition using BIA \[[@B14][@B15][@B16]\].

SUPER-GUC also has several limitations. Since it is a single-center cohort, it is difficult to enroll a large patient number and difficult to represent whole population. However, its flexible design and open structure can expend SUPER-GUC for multi-center collaboration. Actually, SUPER-PC-Active Surveillance (AS) is being adapted for a nationwide, multicenter cohort of the Korean Urological Oncology Society by reducing variables and restructuring the eCRF. Because non-surgical sub-cohorts were opened later, numbers of patients in these sub-cohorts are relatively small. An outpatient-based patient recruiting system has been recently established. Therefore, we expect a rapid increase in the size of non-surgical sub-cohorts. Furthermore, although inherent bias from an observational study is inevitable, it may be minimized using a recent statistical adjusting methodology \[[@B6][@B26][@B27]\].

There are many prospective cohorts in the uro-oncology field; however, they are for specific cancer types and are generally limited to specific disease conditions or treatments \[[@B19][@B24][@B28][@B29][@B30]\]. To our knowledge, SUPER-GUC is the first comprehensive, prospective, bio-bank-linked cohort covering all major genitourinary cancers for all disease statuses and treatments.

CONCLUSIONS
===========

In summary, we successfully established a comprehensive, prospective, multidisciplinary, bio-bank-linked genitourinary cancer cohort, SUPER-GUC. It will support a variety of research regarding comparative outcomes, QoL studies, and translational research such as genetic or biomarker studies for prostate, kidney, and UCs.
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###### Sub-cohorts of the SUPER-GUC and their eligibility criteria

![](icu-60-235-i001)

  Cohort            Eligibility criteria
  ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SUPER-PC          
   SUPER-PC-RP      Pathologically proven prostate cancer patients who undergo radical prostatectomy
   SUPER-PC-AS      Pathologically proven low risk prostate cancer patients within 6 months who undergo active surveillance as initial treatment. They should be eligible by strict criteria registered in ClinicalTrials.gov protocol (NCT02971085), when patients want and meet usual active surveillance criteria they can be enrolled as non-strict criteria.
   SUPER-PC-RT      Pathologically proven prostate cancer patients who undergo radiation therapy with curative intent. It includes primary, adjuvant and salvage radiation therapy, but palliative radiation therapy is not eligible.
   SUPER-PC-HSPC    Pathologically proven non-metastatic or metastatic hormone sensitive prostate cancer patients who undergo medical therapy as major initial treatment. It includes watchful waiting, ADT and chemo-ADT. Neoadjuvant or adjuvant medical therapy for other major treatment is not eligible.
   SUPER-PC-CRPC    Pathologically proven prostate cancer patients, who were progressed as CRPC within 3 months.
  SUPER-RCC         
   SUPER-RCC-Nx     Clinically diagnosed as renal cell carcinoma patients who undergo surgical treatment. It includes ablation, partial or radical nephrectomy. It is not limited to localized cancer, thus cytoreductive nephrectomy in metastatic disease is also eligible.
   SUPER-RCC-mRCC   Pathologically proven renal cell carcinoma patients who were diagnosed as advanced (T4 or N1) or metastatic disease within 3 months and undergo initial treatment for advanced or metastatic RCC. Nephrectomy or metastasectomy before pathologic diagnosis does not limit the enrollment.
  SUPER-UC          
   SUPER-UC-TURB    Clinically diagnosed as bladder cancer patients who undergo transurethral resection of bladder tumor.
   SUPER-UC-Cx      Pathologically proven bladder cancer patients who undergo radical cystectomy.
   SUPER-UC-UTUC    Clinically diagnosed as upper urinary tract urothelial cancer patients who undergo curative surgical treatment for it. It includes nephroureterectomy, segmental ureterectomy and any kind of nephron sparing endoscopic treatment. It also includes definitive treatment plan after intraoperative decision by ureteroscopy with or without frozen biopsy.
   SUPER-UC-mUC     Pathologically proven urothelial cancer patients who were diagnosed as advanced (non-localized or lymph node involve- ment) or metastatic disease within 3 months and undergo initial treatment for advanced or metastatic urothelial cancer.

SUPER, Seoul National University Prospectively Enrolled Registry; GUC, Genitourinary Cancer; PC, prostate cancer; RP, radical prostatectomy; AS, active surveillance; RT, radiation therapy; HSPC, hormone-sensitive prostate cancer; ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; RCC, renal cell carcinoma; Nx, nephrectomy; mRCC, metastatic renal cell carcinoma; UC, urothelial cancer; TURB, transurethral resection of bladder tumor; Cx, cystectomy; UTUC, upper urinary tract urothelial cancer; mUC, metastatic urothelial cancer.

###### Architecture of electronic case-report forms for Seoul National University Prospectively Enrolled Registry for Prostate Cancer-Radical Prostatectomy (SUPER-PC-RP)
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  Name of form                 Number of fields   Entering type         Description and examples
  ---------------------------- ------------------ --------------------- -----------------------------------------------------------------------------------------------------------------
  Study data & demographics    39                 Once entering         Study number, basic demographics and bio-banking information
  Preop. characteristics       54                 Once entering         Initial PSA, biopsy information, past medical, social and family history
  Preop. imaging               19                 Once entering         Results of magnetic resonance imaging and bone scan
  Operation                    38                 Once entering         Details of surgery
  Pathology                    50                 Once entering         Final pathology details
  Postop. outcomes             9                  Once entering         Short-term postoperative results such as duration of hospital stay, cystography and Foley catheter removal date
  Complication                 31                 Once entering         Intraoperative, immediate, 30 and 90 days complications
  Lab                          35                 Repeatedly entering   Laboratory results (except PSA)
  PSA                          202                Revisingly entering   PSA results
  Medication & comorbidity     22                 Repeatedly entering   Information of medication and comorbidity
  A/E                          62                 Repeatedly entering   Post-treatment adverse events
  IPSS                         14                 Repeatedly entering   International Prostate Symptom Score questionnaire
  EPIC-CP                      26                 Repeatedly entering   Expanded Prostate Cancer Index Composite for Clinical Practice questionnaire
  IIEF-5                       9                  Repeatedly entering   International Index of Erectile Function-5 questionnaire
  EQ-5D-5L                     10                 Repeatedly entering   EuroQol health-related utility measurement tool
  CARE questionnaire           35                 Repeatedly entering   Convalescence And Recovery Evaluation questionnaire
  G8                           10                 Once entering         Geriatric assessment by the G8
  InBody                       26                 Repeatedly entering   Body composition measurement by bio-electrical impedance analysis
  Functional outcome summary   30                 Revisingly entering   Summarized results of continence and potency
  Oncologic outcome summary    63                 Revisingly entering   Adjuvant or salvage treatment and oncologic outcome results

Preop., preoperative; postop., postoperative; PSA, prostate-specific antigen.

###### Patient enrollment status of Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC) at the end of December, 2018

![](icu-60-235-i003)

  Cohort            First enrollment date   Number of patients
  ----------------- ----------------------- --------------------
  SUPER-PC                                  929
   SUPER-PC-RP      March 6, 2016           765
   SUPER-PC-AS      December 23, 2016       56
   SUPER-PC-RT      May 20, 2016            39
   SUPER-PC-HSPC    October 18, 2016        56
   SUPER-PC-CRPC    April 3, 2017           
  SUPER-RCC                                 796
   SUPER-RCC-Nx     March 10, 2016          762
   SUPER-RCC-mRCC   June 2, 2016            34
  SUPER-UC                                  1,221
   SUPER-UC-TURB    March 21, 2016          859
   SUPER-UC-Cx      March 21, 2016          170
   SUPER-UC-UTUC    March 7, 2016           163
   SUPER-UC-mUC     March 28, 2016          29

SUPER, Seoul National University Prospectively Enrolled Registry; PC, prostate cancer; RP, radical prostatectomy; AS, active surveillance; RT, radiation therapy; HSPC, hormone-sensitive prostate cancer; CRPC, castration-resistant prostate cancer; RCC, renal cell carcinoma; Nx, nephrectomy; mRCC, metastatic renal cell carcinoma; UC, urothelial cancer; TURB, transurethral resection of bladder tumor; Cx, cystectomy; UTUC, upper urinary tract urothelial cancer; mUC, metastatic urothelial cancer.

###### Participation, banking rates, and baseline characteristics of surgical sub-cohorts in SUPER-GUC

![](icu-60-235-i004)

  Characteristic               SUPER-PC-RP      SUPER-RCC-Nx     SUPER-UC-TURB    SUPER-UC-Cx      SUPER-UC-UTUC
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  No. of patients enrolled     765              762              859              170              163
  Participation rate^a^        765/836 (91.5)   762/853 (89.3)   859/964 (89.1)   170/191 (89.0)   163/175 (93.1)
  Bio-specimen sampling rate   758/765 (99.1)   733/762 (96.2)   829/859 (96.5)   155/170 (91.2)   155/163 (95.1)
  Tumor banking                463/765 (60.5)   565/762 (74.1)   489/859 (56.9)   117/170 (68.8)   129/163 (79.1)
  Baseline characteristics                                                                         
   Age (y)                     68.7±6.6         59.4±12.4        68.9±11.9        67.0±10.9        68.5±9.9
   Sex                                                                                             
    Male                       765 (100.0)      521 (68.4)       687 (80.0)       128 (75.3)       113 (69.3)
    Female                     0 (0.0)          241(31.6)        172 (20.0)^b^    42 (24.7)        50 (30.7)
   Clinical T stage                                                                                
    ≤T1                        674 (88.1)       658 (86.4)       568 (66.1)       59 (34.7)        123 (75.5)
    T2                         79 (10.3)        63 (8.3)         86 (10.0)^c^     88 (51.8)        17 (10.4)
    T3                         12 (1.6)         38 (5.0)         \-               15 (8.8)         22 (13.5)
    T4                         0 (0.0)          3 (0.4)          \-               8 (4.7)          1 (0.6)
    Tx                         0 (0.0)          0 (0.0)          205 (23.9)d      0 (0.0)          0 (0.0)
   Clinical N stage                                                                                
    N0                         672 (87.8)       738 (96.9)       \-               145 (85.3)       145 (89.0)
    N+                         86 (11.2)        24 (3.1)         \-               25 (14.7)        18 (11.0)
    Nx                         7 (0.9)          0 (0.0)          \-               0 (0.0)          0 (0.0)
   Clinical M stage                                                                                
    M0                         738 (96.5)       738 (96.9)       \-               169 (99.4)       162 (99.4)
    M+                         0 (0.0)          24 (3.1)         \-               1 (0.6)          1 (0.6)
    Mx                         27 (3.5)         0 (0.0)          \-               0 (0.0)          0 (0.0)

Values are presented as number only, number/total number (%), mean±standard deviation, or number (%).

SUPER, Seoul National University Prospectively Enrolled Registry; GUC, Genitourinary Cancer; PC, prostate cancer; RP, radical prostatectomy; RCC, renal cell carcinoma; Nx, nephrectomy; UC, urothelial cancer; TURB, transurethral resection of bladder tumor; Cx, cystectomy; UTUC, upper urinary tract urothelial cancer.

^a^:Percentage of patients enrolled among all eligible patients, ^b^:pathologic stage of first TURB after enrolled, ^c^:pathologic stage ≥T2, ^d^:pathologic T0 or benign.
